Ordenar

Buscar

01/05/2026 Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo-controlled exploratory study
Garcia-Pagan, JC, Gluud, LL, Mandorfer, M, Schattenberg, JM, De Gottardi, A, Berzigotti, A, Fortea, JI, Martínez, AA, Alvarado-Tapias, E, Berning, M, Petryszyn, P, Henricson, E, Berglind, N, Lin, M, Persson, K, Mercier, A, Ambery, P, Bosch, J, Oscarsson, J, Rockey, DC. Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo-controlled exploratory study. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2026; 92(5)DOI:10.1002/bcp.70332. PMID:41362018. IF:3.000(Q2/4D).
01/05/2026 Antithrombotic and management of small bowel bleeding - time to throw caution into the wind?
Scaramella, L, Cosenza, A, Romero-Mascarell, C, Elli, L. Antithrombotic and management of small bowel bleeding - time to throw caution into the wind?. CURRENT OPINION IN GASTROENTEROLOGY. 2026; 42(3)DOI:10.1097/MOG.0000000000001160. PMID:41700996. IF:2.500(Q2/5D).
01/05/2026 Baseline and 4-year associations between prediabetes and kidney impairment: Insights from the ILERVAS cohort
Izarra, A, Bermúdez-López, M, Valdivielso, JM, Pamplona, R, Torres, G, Mauricio, D, Castro-Boqué, E, Fernández, E, Simó, R, Hernández, C, Lecube, A. Baseline and 4-year associations between prediabetes and kidney impairment: Insights from the ILERVAS cohort. DIABETES OBESITY & METABOLISM. 2026; 28(5)DOI:10.1111/dom.70560. PMID:41705635. IF:5.700(Q1/2D).
01/05/2026 Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration
Dingemans, AMC, Opitz, I, Brunelli, A, Remon, J, Hendriks, LE, Edwards, J, Faivre-Finn, C, Reguart, N, Smit, EF, Levy, A, Sanchez-Lorente, D, Trujillo, JC, Filippi, AR, Stathopoulos, K, Blum, TG, Guckenberger, M, Popat, S, De Angelis, R, Hofman, P, von der Thüsen, J, Hartemink, KJ, Petersen, RH, Ruffini, E, Dickhoff, C, Houda, I, Prisciandaro, E, De Ruysscher, D, Derks, J, Bahce, I, Mariolo, A, Besse, B, Xenophontos, E, Levra, NG, van Schil, P, Brandao, M, Berghmans, T. Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration. Lancet Respiratory Medicine. 2026; 14(5)DOI:10.1016/S2213-2600(26)00051-2. PMID:41895314. IF:32.800(Q1/1D).